MONTREAL--(BUSINESS WIRE)--Gemin X Biotechnologies, Inc. announced today that results from a preclinical study of GX15-070 in mantle cell lymphoma (MCL) cell lines and ex vivo patient samples showed that GX15-070 and bortezomib (Velcade) exhibit synergistic activity, due to the ability of GX15-070 to potently antagonize the Bcl-2 family member, Mcl-1. Gemin X co-founder and chief scientific officer Gordon Shore, Ph.D., presented these data (Abstract 832) at the American Society of Hematology’s 48th Annual Meeting and Exposition, December 9-12 in Orlando, FL during an oral presentation titled “Obatoclax (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma.”
